Testing a new immune cell therapy for nerve and muscle diseases

Plain-English translation of NCT07304154 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This study is testing a new treatment called that uses your own immune cells to help people whose autoimmune neurologic diseases have not responded well to standard treatments. Researchers want to learn whether this medication is safe and whether it can reduce symptoms of conditions like multiple sclerosis, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. This is an early-stage trial to determine the right dose and see how well the treatment works.

Some people with autoimmune nerve and muscle diseases don't improve enough with current medications, or they can't tolerate the side effects. This medication represents a new approach that may help patients who have run out of other options.

Do you qualify?

You likely qualify if…

you have been diagnosed with multiple sclerosis, myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy that has not adequately responded to previous treatments
you have either experienced disease activity despite being on strong medications, or you have not been able to tolerate at least two different types of standard treatments due to side effects
for multiple sclerosis: you have specific disability levels (EDSS scores) within the study's acceptable range and meet imaging or clinical activity criteria
for myasthenia gravis: you have documented autoantibodies and moderate to severe generalized weakness despite being on at least two classes of immunosuppressive medications
for CIDP: you have probable or definite disease that has not improved despite standard care or that you cannot tolerate standard treatments
you are willing to use contraception if you can become pregnant

You likely don't qualify if…

you are pregnant or breastfeeding
you have severe infections or other serious medical conditions that would make it unsafe to receive chemotherapy
you have certain types of cancer or a history of cancer within a specific timeframe
you are unable or unwilling to follow the study's requirements for monitoring and follow-up visits

What participation looks like

If you join this trial, you will first receive chemotherapy medications ( and ) to prepare your immune system. Your own immune cells will then be collected, specially modified in a laboratory, and given back to you as an infusion. You will be closely monitored with regular clinic visits, blood tests, and imaging studies to watch for side effects and to see how well the treatment is working. The study involves two phases: an initial phase to find the right dose, and a larger phase to test that dose in more patients.

AI-generated summary from trial data · Jul 10, 2026 · Not medical advice

Trial locations(6 sites)

United States

Stanford Neuroscience Health Center, Palo Alto, California

Columbia University Irving Medical Center, New York, New York

LDS Hospital - Intermountain Health, Salt Lake City, Utah

Fred Hutchinson Cancer Center, Seattle, Washington

Australia

Concord Repatriation General Hospital, Sydney, New South Wales